🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

LeMaitre Vascular, Inc. LMAT R2K

Healthcare · Medical Instruments & Supplies · United States
https://www.lemaitre.com

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

READ MORE ›
$94.65
+16.20% 1Y

Market & Price

Market Cap
$2.16B
Current Price
$94.65
High / Low (52W)
$117.10 / $79.04
Beta
0.60

Valuation

Stock P/E
34.80
Industry PE
23.65
Forward P/E
29.07
PEG Ratio
2.63
Book Value
$17.80
Price to Book
5.32
P/S
8.44
EV/EBITDA
25.21
Dividend Yield
1.06%

Profitability & Returns

ROCE
13.87%
ROE
16.55%
ROA
7.20%
Profit Margin
24.35%
Op Margin
26.71%
EPS (Latest Qtr)
$0.68
EPS (TTM)
$2.72

Balance Sheet & Liquidity

Debt/Equity
0.47
Quick Ratio
12.08
Current Ratio
14.32
Debt
$189.82M
Total Assets
$615.69M
Current Assets
$468.23M
Working Capital
$431.91M

Ownership

Promoter Holding
6.56%
Chg in Prom Hold
-
FII / Inst Holding
100.41%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$1.99B
Total Revenue (TTM)
$256.28M
EBITDA
$78.75M
Free Cash Flow
$53.27M
Operating Cash Flow
$87.31M
Shares Outstanding
22.85M
Gross Margin
71.33%
Payout Ratio
31.25%

Growth (CAGR)

Revenue 5Y
15.58%
Profit 5Y
40.91%
Revenue (YoY)
11.20%
Earnings (YoY)
41.70%

PROS

  • Excellent profit margin of 24.3%.
  • Compounding revenue at 15.6% over 5 years.
  • Profit CAGR of 40.9% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 LMAT LeMaitre Vascular, Inc. R2K 94.65 34.80 $2.16B 1.06% 13.87% 16.55% 15.58% 40.91%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ---24.14M25.75M24.82M-25.99M27.02M24.16M-28.48M29.48M29.10M-30.55M24.85M36.42M-35.88M40.67M38.37M-39.56M39.03M39.03M-47.08M50.12M47.41M-53.48M55.85M--59.87M64.23M61.05M64.45M66.55M
Cost of Revenue -----------------------------------18.45M19.26M15.09M18.26M18.16M
Gross Profit 15.37M17.02M16.19M17.35M17.52M17.58M18.25M18.47M18.99M17.25M19.22M19.46M20.32M20.17M19.91M20.48M17.03M22.70M24.40M23.80M26.76M24.87M25.96M25.96M27.81M25.07M26.05M30.88M32.09M30.82M33.27M36.66M38.47M--41.42M44.97M45.95M46.19M48.40M
Operating Expenses -----------------------------------28.79M28.83M25.64M27.36M30.62M
Operating Income 3.78M5.34M3.91M4.19M5.54M5.05M6.32M4.86M11.54M4.61M7.19M4.43M5.92M5.91M4.93M4.35M4.87M10.02M9.54M7.95M11.11M9.07M8.30M7.93M5.78M6.15M6.97M7.87M9.45M9.18M10.21M11.87M14.38M--12.63M16.14M20.31M18.83M17.77M
EBITDA -----------------------------------18.08M22.02M26.48M24.20M23.59M
Interest Expense -----------------------------------1.29M1.30M1.30M1.30M1.30M
Pretax Income -----------------------------------14.24M18.07M22.57M20.30M19.67M
Tax Provision -----------------------------------3.23M4.29M5.21M4.72M3.99M
Net Income 2.60M3.23M2.60M3.22M4.63M5.04M4.28M3.85M8.75M4.31M6.03M3.51M4.62M5.18M4.61M3.17M3.50M7.51M7.03M5.93M8.30M6.50M6.17M6.04M3.52M5.46M5.63M6.04M8.10M7.50M8.46M9.89M11.83M--11.01M13.78M17.36M15.58M15.68M
Diluted EPS 0.140.170.130.160.230.250.210.190.430.210.300.170.230.250.230.160.170.370.340.280.400.300.280.270.160.250.250.270.360.330.380.440.52--0.480.600.750.680.68
R&D Expense 1.63M1.54M-1.66M1.63M1.76M-1.82M1.99M2.04M-2.24M2.26M2.28M-2.99M2.14M2.10M-2.84M2.65M2.85M-2.93M3.35M3.46M-3.88M4.52M4.22M-4.09M4.28M3.66M-4.09M3.54M2.97M-4.06M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue --------100.87M105.57M117.23M129.37M-161.65M193.48M219.86M249.60M
Cost of Revenue -------------56.76M66.44M68.96M71.06M
Gross Profit 37.30M41.72M40.23M40.87M45.12M48.43M54.17M62.94M70.70M73.94M79.85M84.62M-104.90M127.05M150.90M178.54M
Operating Expenses -------------74.96M89.85M98.64M110.63M
Operating Income 1.95M4.01M3.69M4.24M4.52M6.34M11.51M16.34M21.10M28.21M21.18M28.79M-29.94M37.20M52.26M67.91M
EBITDA -------------36.92M48.99M66.69M90.79M
Interest Expense -------------00205.00K5.18M
Pretax Income -------------27.49M39.48M56.88M75.18M
Tax Provision -------------6.85M9.37M12.84M17.45M
Net Income 1.60M6.01M2.14M2.57M3.20M3.92M7.76M10.59M17.18M22.94M17.93M21.22M-20.64M30.11M44.04M57.73M
Diluted EPS 0.100.370.130.160.200.230.420.550.861.130.881.04-0.931.341.932.52
R&D Expense 5.91M5.49M4.42M5.09M5.24M4.67M5.48M6.14M6.64M8.20M9.28M10.10M11.80M13.29M16.97M15.65M14.14M

Compounded Sales Growth

5 Years:15.58%
1 Year:11.20%

Compounded Profit Growth

5 Years:40.91%
1 Year:41.70%

Stock Price Performance

1 Year:+16.20%
6 Months:+13.91%
3 Months:-12.09%
1 Month:-11.55%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --63.27M59.69M63.06M70.49M81.49M90.70M101.92M126.32M153.09M188.34M252.81M-310.48M346.78M551.82M615.69M
Current Assets --------------161.73M194.60M402.19M468.23M
Cash & Equivalents 15.89M23.19M22.61M20.13M16.45M14.71M18.69M27.45M24.29M19.10M26.32M11.79M26.76M-19.13M24.27M25.61M28.24M
Inventory --------------45.28M52.33M55.94M58.25M
Receivables --------------22.04M25.06M30.06M33.61M
Total Liabilities --10.92M7.60M10.17M13.93M13.29M12.82M14.42M16.55M22.85M40.20M80.24M-42.27M48.88M214.53M222.17M
Current Liabilities --10.39M6.54M8.39M10.22M10.04M10.37M10.48M13.19M19.76M20.85M25.14M-25.33M29.88M30.61M36.32M
Long Term Debt ----------------167.77M168.65M
Total Debt --------------16.60M19.09M185.69M185.59M
Total Equity 45.75M48.21M52.36M52.09M52.89M56.56M68.21M77.88M87.50M109.77M130.24M148.14M172.57M-268.20M297.90M337.29M393.52M
Shares Outstanding --------------23.66M23.91M24.15M24.40M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 5.44M7.05M3.17M4.72M5.39M--16.90M22.87M19.51M14.18M34.80M-25.38M36.75M44.12M81.25M
Investing Cash Flow 2.18M-5.24M-1.82M-5.20M-6.19M---17.21M-28.96M-7.05M-24.10M-52.89M--10.37M-24.71M-200.12M-64.94M
Financing Cash Flow -376.00K-2.33M-3.80M-3.16M-961.00K---2.58M80.00K-4.42M-4.62M32.16M--9.23M-7.13M158.10M-14.54M
Capital Expenditure -577.00K-2.47M-2.02M-1.21M-2.73M-1.17M-2.27M-2.84M------3.23M-7.26M-6.96M-6.78M
Free Cash Flow 4.86M4.58M1.15M3.51M2.65M--14.05M-----22.15M29.49M37.16M74.47M
Net Change in Cash -------------5.77M4.91M2.11M1.77M
Share Buybacks 686.00K2.52M2.21M2.02M373.00K211.00K266.00K311.00K778.00K741.00K683.00K570.00K802.00K642.00K853.00K1.72M1.82M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------70.1%70.0%68.1%65.4%-64.9%65.7%68.6%71.5%
Operating Margin % --------20.9%26.7%18.1%22.3%-18.5%19.2%23.8%27.2%
Net Margin % --------17.0%21.7%15.3%16.4%-12.8%15.6%20.0%23.1%
ROE % 3.3%11.5%4.1%4.9%5.7%5.7%10.0%12.1%15.6%17.6%12.1%12.3%-7.7%10.1%13.1%14.7%
ROCE % -7.6%6.9%7.8%7.5%8.9%14.3%17.9%18.7%21.2%12.6%12.6%-10.5%11.7%10.0%11.7%

Shareholding Pattern

Insiders
6.56%
Institutions
100.41%
Public Float
107.46%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 13.76% 3.14M $297.59M
2 Conestoga Capital Advisors, LLC 6.46% 1.48M $139.78M
3 First Trust Advisors LP 4.37% 998.07K $94.47M
4 Vanguard Capital Management LLC 3.99% 912.06K $86.33M
5 Copeland Capital Management, LLC 3.81% 870.69K $82.41M
6 State Street Corporation 3.75% 855.78K $81.00M
7 Congress Asset Management Co 3.65% 834.53K $78.99M
8 Geneva Capital Management LLC 3.30% 753.99K $71.37M
9 Geode Capital Management, LLC 2.88% 658.45K $62.32M
10 Vanguard Portfolio Management LLC 2.46% 562.77K $53.27M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LMAT

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks